Dr. Morinaka has been appointed as a Chief Business Officer of Rege Nephro. He has over 10 years of experience in drug discovery research at the University of Tokyo, Osaka University and Astellas Pharma. He has over 10 years in new business creation and venture investment at Astellas and JAFCO.
He previously worked for JAFCO, the top tier VC in Japan, and invested in biotech start-ups. He served as a board member of Chordia Therapeutics, Alchemedicine and Rege Nephro and supported 6 other companies including Cuorips, Modulus Discovery and Logomix.
He also previously worked for Astellas and led 5 projects and created 2 development candidates in oncology. mHealth for patients with overactive bladder was listed in clinical guidelines. He moved to Astellas Venture Management, Astellas CVC in the Bay Area, to find start-ups that could lead to new business.
He received Ph.D. in Life Sciences with Dean Prize from the University of Tokyo. He holds MBA from Waseda Business School.
He previously worked for JAFCO, the top tier VC in Japan, and invested in biotech start-ups. He served as a board member of Chordia Therapeutics, Alchemedicine and Rege Nephro and supported 6 other companies including Cuorips, Modulus Discovery and Logomix.
He also previously worked for Astellas and led 5 projects and created 2 development candidates in oncology. mHealth for patients with overactive bladder was listed in clinical guidelines. He moved to Astellas Venture Management, Astellas CVC in the Bay Area, to find start-ups that could lead to new business.
He received Ph.D. in Life Sciences with Dean Prize from the University of Tokyo. He holds MBA from Waseda Business School.
Speaking In
4:00 PM - 4:15 PM
Tuesday, June 6
